DRUG
Recombinant Human Thymosin β4
Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
Status
Completed
Phase
Phase 1
Enrollment
30
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin β4（NL005）or placebo 0.5, 2.0,5.0μg/kg in Chinese healthy volunteers.30 volunteers will be randomly assigned to one of three groups to receive either NL005 or placebo for 10 consecutive days.
Full detailed description
This study was a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability pharmacokinetics and potential immune responses of multiple NL005 intravenous administration. Three groups of 30 subjects will receive an NL005 or placebo dose of 0.5μg/kg 2.0 μg/kg and 5.0 μg/kg for 10 consecutive days at a ratio of 4:1. While observing the safety of the subjects in each dose group, about 5mL of venous blood was collected for the ADA study in healthy subjects 14 days and 28 days after the first administration of the drug.
Interventions
Treatment arms and agents.
OTHER
Placebo
3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
Timeline
From registration to results.
First posted
Sep 21, 2020
Study start
Jul 30, 2018
Primary completion
Feb 18, 2019
Study completion
Jul 26, 2019
Results posted
Not reported
Registry updated
Sep 29, 2020
Outcomes
What the study measures.
Primary outcomes
Maximum Tolerated Dose (MTD) .
Time frame · Day-7、-1、1、2、3、4、5、6、7、8、9、10、14、28.
Determine maximum tolerated dose (MTD) or dose-limiting toxicity (DLT) by comprehensive evaluation of drug safety by adverse event observation, vital signs, physical examination, laboratory examination, electrocardiogram, etc. In this study, DLT was defined as liver, kidney, heart and mental nervous system toxicity of level 2 or above or blood system toxicity of level 3 or above and other systemic adverse events occurred within 14 days after drug administration, and the adverse events were judged to be related to the experimental drug use.If more than 3 (including 3) DLT cases are present in any dose group, the test should be terminated. The previous dose of this dose is considered the maximum tolerated dose (MTD).
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.
Time frame · Day-7、-1、1、2、3、4、5、6、7、8、9、10、14、28.
Determine maximum tolerated dose (MTD) or dose-limiting toxicity (DLT) by comprehensive evaluation of drug safety by adverse event observation, vital signs, physical examination, laboratory examination, electrocardiogram, etc. All adverse events were determined according to NCI CTCAE4.03.CTCAE4.03 was classified into grades 1 to 5, in which grade 1 was mild adverse event and grade 5 was death due to adverse event.According to NCI CTCAE4.03.
The Cmax of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
The Tmax of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
The MRT of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
The AUClast of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
The AUC0-inf of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
The t1/2 of multiple administration of rh-Tβ4.
Time frame · Day 1、2、3、4、5、6、7、8、9、10.
Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tβ4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 50 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Chinese healthy volunteers（male or female）. 2. Between 18 and 50 years of age. 3. Female subjects should weigh no less than 45 kg and male subjects should weigh no less than 50 kg.BMI between 19 and 28 kg/m2. 4. Good health condition, no history of unintentional, liver, kidney, digestive tract, immune system, nervous system, mental and metabolic abnormality, no family history of tumor. 5. Ability to communicate normally with medical staff, understand research requirements and comply with hospital regulations. 6. Voluntarily sign informed consent. Exclusion Criteria: 1. Physical examination vital signs electrocardiogram and laboratory examination are not done or any result is judged to be clinically significant abnormal (judged by clinician). 2. ADA tests positive. 3. Smoking more than 5 cigarettes a day for the previous 3 months, or no guarantee to stop smoking during the trial. 4. Previous history of substance abuse or drug screening test positive. 5. Alcohol intake averaged more than 2 units per day (1 unit = 360mL beer,150mL wine or 45mL 40% alcohol liquor) or alcohol test positive in the first 3 months of inclusion. 6. Participated in another trial or used this drug within 3 months before inclusion. 7. Any other drug was used within two weeks before the trial. 8. There is a significant clinical history of allergy, especially for drugs, protein preparations and biological products, especially for rh-tβ4 or any of its ingredients. 9. Blood donation or blood loss was equal to or greater than 400 mL within three months prior to the trial. 10. Female subjects who are pregnant or breast-feeding, or who are likely to become pregnant without using an acceptable method of contraception, or who are positive for a pregnancy test, and male subjects who are not using effective contraception or whose partner has a family planning plan within six months of the end of the trial. 11. Unable to tolerate venous blood collection. 12. There is no guarantee that smoking and taking grapefruit juice or any alcoholic and xanthine food and beverage (including chocolate, tea, coffee, cola, etc.) from 48 hours before administration to the last blood sample collection. 13. The investigator judges that the subject is unable to complete the study or otherwise considers that the subject's participation in the study may cause other injury.
Study locations
1 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
Beijing Shijitan Hospital
Beijing, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Thymosin Beta-4.
NCT IDStudyPhase / statusEnrollmentUpdated
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction (AMI) · Acute Myocardial Infarction of Anterior Wall
Phase 2
Not yet recruiting
189
2026-05
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Hudson Biotech · Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction
Phase 1 / Phase 2
Recruiting
80
2026-03
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLC · Neurotrophic Keratopathy
Phase 3
Recruiting
70
2025-12
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction
Phase 2
Completed
90
2024-06
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction
Phase 2
Completed
62
2022-08
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC · Dry Eye Syndromes · Dry Eye
Phase 3
Completed
700
2022-05
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC · Dry Eye Syndrome
Phase 3
Completed
601
2022-01
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
RegeneRx Biopharmaceuticals, Inc. · Acute Myocardial Infarction · ST Elevation Myocardial Infarction
Phase 2
Withdrawn
0
2021-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.